<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-151633</identifier>
<setSpec>0212-8241</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Repermeabilization of renal artery stenosis in a patient with nephrotic syndrome secondary to primary antiphospholipid syndrome. A rare presentation</dc:title>
<dc:description xml:lang="en">Primary antiphospholipid syndrome (PAPS) is a clinical condition whose most frequent manifestation from the renal point of view is hypertension, nephrotic syndrome being a rare presentation form. The prevalence of renal artery stenosis in this syndrome as well as its evolution and treatment are unknown. From the therapeutic point of view, anticoagulation with dicumorinics is indicated in PAPS. An attempt should be made to obtain an international normalized ratio (INR) &gt; 3 to prevent progression of the thrombotic events and renal disease. We present the case of a 30-year old male diagnosed of primary antiphospholipid syndrome. In spite of having renal artery thrombosis, he had a mild deterioration of renal function without hypertension (AU)</dc:description>
<dc:creator>Pérez Bañasco, V</dc:creator>
<dc:creator>Polaina Rusillo,  M</dc:creator>
<dc:creator>Cazalla Cadenas, F</dc:creator>
<dc:creator>Liébana Cañada, A</dc:creator>
<dc:creator>Vallejo Miñarro, J</dc:creator>
<dc:creator>Biechy Baldán, MM</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">El síndrome antifosfolípido primario (SAFP) es una entidad clínica que tiene como manifestación más frecuente desde el punto de vista renal la hipertensión, mientras que el síndrome nefrótico es infrecuente. La prevalencia de estenosis de arteria renal en este síndrome es desconocida, al igual que su evolución y tratamiento. Desde el punto de vista terapéutico, en el SAFP está indicada la anticoagulación con dicumorínicos para lograr una ratio normalizada internacional (INR) &gt; 3 para evitar que progresen los eventos trombóticos y la enfermedad renal. A continuación presentamos el caso de un varón de 30 años que diagnosticamos de síndrome antifosfolípido primario que a pesar de presentar una trombosis de arteria renal presentó un ligero deterioro de la función renal sin hipertensión (AU)</dc:description>
<dc:source>Hipertensión (Madr., Ed. impr.);25(5): 214-217, sept. 2008. tab, ilus</dc:source>
<dc:identifier>ibc-151633</dc:identifier>
<dc:title xml:lang="es">Repermeabilización de estenosis de arteria renal en paciente con síndrome nefrótico secundario a síndrome antifosfolípido primario. Una inusual presentación clínica</dc:title>
<dc:subject>^d12499^s22016</dc:subject>
<dc:subject>^d9596^s22044</dc:subject>
<dc:subject>^d9596^s22012</dc:subject>
<dc:subject>^d9596^s22053</dc:subject>
<dc:subject>^d21012</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d7152^s22053</dc:subject>
<dc:subject>^d8354^s22044</dc:subject>
<dc:subject>^d30257^s22044</dc:subject>
<dc:subject>^d30257^s22011</dc:subject>
<dc:subject>^d8354^s22012</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d1178^s22016</dc:subject>
<dc:subject>^d7152^s22016</dc:subject>
<dc:subject>^d1178^s22053</dc:subject>
<dc:subject>^d12499^s22062</dc:subject>
<dc:subject>^d12499^s22012</dc:subject>
<dc:subject>^d12499^s22044</dc:subject>
<dc:subject>^d9596^s22016</dc:subject>
<dc:subject>^d1178^s22044</dc:subject>
<dc:subject>^d1178^s22012</dc:subject>
<dc:type>article</dc:type>
<dc:date>200809</dc:date>
</metadata>
</record>
</ibecs-document>
